Verso et al reported the Protecht score for identifying a cancer patient at increased risk for venous thromboembolism. The score is a modification of the Khorana Risk Score. The authors are from multiple institutions in Italy.
Protecht is derived from Prophylaxis of Thromboembolism during Chemotherapy.
Parameters:
(1) tumor risk for venous thromboembolism
(2) prechemotherapy anemia (hemoglobin or use of erythropoietin stimulating agent)
(3) prechemotherapy white blood cell count
(4) prechemotherapy platelet count
(5) body mass index
(6) chemotherapy with Gemcitabine
(7) chemotherapy with platinum-based agent
Parameter
Finding
Points
tumor risk
very high (gastric, pancreas)
2
high (lung, ovarian, bladder)
1
other
0
prechemotherapy anemia
hemoglobin < 10 g/dL
1
receiving erythropoietin stimulating agent
1
other
0
prechemotherapy WBC
<= 11 * 10^9/L
0
> 11 * 10^9/L
1
prechemotherapy platelet count
< 350 * 10^9/L
0
>= 350 * 10^9/L
1
body mass index
<= 35 kg per square m
0
> 35 kg per square m
1
Gemcitabine chemotherapy
no
0
yes
1
platinum-based chemotherapy
no
0
yes
1
total score =
= SUM(points for all 7 parameters)
Interpretation:
• minimum score: 0
• maximum score: 8
• A score >= 3 is associated with high risk of venous thromboembolism.
To read more or access our algorithms and calculators, please log in or register.
